Location of Repository

Treatment Outcomes of Treatment-Naïve Hepatitis C Patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts

By Anna Davies, Kasha P Singh, Zara Shubber, Philipp Ducros, Edward J Mills, Graham Cooke and Nathan Ford

Abstract

Co-infection with Hepatitis C (HCV) and HIV is common and HIV accelerates hepatic disease progression due to HCV. However, access to HCV treatment is limited and success rates are generally poor

Year: 2013
DOI identifier: 10.1371/journal.pone.0055373
OAI identifier: oai:fieldresearch.msf.org:10144/279013
Provided by: MSF Field Research
Journal:

Suggested articles

Preview

Citations

  1. (2010). A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clinical gastroenterology and hepatology : the official clinical practice journal of the
  2. (2010). Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients.
  3. (1996). An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.
  4. (2010). Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane database of systematic reviews:
  5. (2005). Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clinical infectious diseases : an official publication of the Infectious Diseases
  6. (2010). Changes in liver stiffness in patients with chronic hepatitis C with and without HIV coinfection treated with pegylated interferon plus ribavirin.
  7. (2001). Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin.
  8. (2009). Chronic hepatitis C in patients co-infected with human immunodeficiency virus in Japan: a retrospective multicenter analysis. Hepatology research : the official journal of the
  9. (2012). Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.
  10. (2012). Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ ribavirin treatment in HIV/HCV co-infected patients.
  11. (2008). Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clinical infectious diseases : an official publication of the Infectious Diseases
  12. (2011). Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
  13. (2011). Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
  14. (2012). Effectiveness of hepatitis B treatment in clinical practice.
  15. (2009). Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clinical infectious diseases : an official publication of the Infectious Diseases
  16. (2006). Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS research and human retroviruses 22:
  17. (2003). Efficacy and tolerance of HCV treatment in HIV-HCV coinfected patients: the potential interaction of PI treatment.
  18. (2006). Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study.
  19. (2010). Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision. Therapeutics and clinical risk management 6:
  20. (2011). HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin.
  21. (2004). Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality,
  22. (2009). Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. Journal of acquired immune deficiency syndromes 52:
  23. (2011). Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic.
  24. (2011). High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic.
  25. (2002). Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.
  26. (2009). Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients.
  27. (2007). Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection.
  28. (2007). Improved cognitive function as a consequence of hepatitis C virus treatment.
  29. (2012). Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-alpha 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.
  30. (2010). Institute of Medicine recommendations for the prevention and control of hepatitis
  31. (2009). Iorio A
  32. (2008). IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
  33. (2006). Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
  34. (1999). Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.
  35. (2003). Measuring inconsistency in meta-analyses.
  36. (1986). Meta-analysis in clinical trials. Controlled clinical trials 7:
  37. (2008). Optimizing hepatitis C therapy in HIV/hepatitis C virus (HCV) coinfected patients: Analysis of HCV viral kinetics on treatment.
  38. (2011). Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients. AIDS research and treatment
  39. (2012). Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
  40. (2010). Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients.
  41. (2009). Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clinical infectious diseases : an official publication of the Infectious Diseases
  42. (2012). Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.
  43. (2008). Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV.
  44. (2008). Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy.
  45. (2010). Sustained virological response according to the type of early virological response in HCV and HCV/HIV. Annals of hepatology 9:
  46. (2011). The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients. Clinical immunology 138:
  47. (2010). The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection.
  48. (2010). The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients.
  49. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
  50. (2008). The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
  51. (2008). Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
  52. (1950). Transformations related to the angular and the square root.
  53. (2011). Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug and alcohol dependence 116:
  54. (2009). Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study.
  55. (2012). Treatment of hepatitis C as prevention: a modeling case study in Vietnam.
  56. (2010). Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. Swiss medical weekly 140:
  57. (2011). Very early prediction of response to HCV treatment with PEG-IFN-alfa2a and ribavirin in HIV/HCV-coinfected patients.
  58. (2011). Why do the results of randomised and observational studies differ?

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.